Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

227579 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-11-30

Study Completion Date

2016-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess safety and effectiveness of direct oral anticoagulants (DOACs) for stroke prevention in patients with non-valvular atrial fibrillation (AF). The comparison of DOACs between themselves is of interest.

The investigators will carry out separate population-based, matched cohort studies, using health administrative databases in nine jurisdictions in Canada, the UK and the US. New users of DOACs for stroke prevention in non-valvular AF will be eligible to enter the cohorts. Follow-up will continue until a hospitalization or emergency department visit for a stroke. The results from the separate sites will be combined by meta-analysis to provide an overall assessment of the safety and effectiveness of the different anticoagulation regimens in stroke prevention in AF.

The investigators hypothesize that different DOACs will have similar safety and effectiveness profiles.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Direct Oral Anticoagulants in Patients with Atrial Fibrillation (DOACs Vs Warfarin)

NCT03596502

Atrial Fibrillation Ischemic Stroke Systemic Embolization +3 more

COMPLETED

Use of Direct Oral Anticoagulants in UK

NCT03119116

Stroke

COMPLETED

Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

NCT01938248

Atrial Fibrillation Stroke

COMPLETED PHASE4

What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?

NCT04436978

Acute Coronary Syndrome Myocardial Infarction Atrial Fibrillation +8 more

RECRUITING PHASE4

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

NCT00412984

Atrial Fibrillation Atrial Flutter

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this study is to assess safety and effectiveness of direct oral anticoagulants (DOACs) for stroke prevention in patients with non-valvular atrial fibrillation (AF).

A common-protocol approach will be used to conduct retrospective cohort studies using administrative health care data from nine jurisdictions (the Canadian provinces of Alberta, British Columbia, Manitoba, Nova Scotia, Ontario, Quebec, Saskatchewan, as well as the United Kingdom (UK) Clinical Practice Research Datalink (CPRD) and the United States (US) Marketscan). Briefly, the Canadian databases include population-level data on physician billing, diagnoses and procedures from hospital discharge abstracts, and dispensations for prescription drugs. The data in Alberta, Nova Scotia, and Ontario will be restricted to patients aged 65 years and older, as prescription data are not available for younger patients. The CPRD is a clinical database that is representative of the UK population and contains the records for patients seen at over 680 general practitioner practices in the UK; these data will be linked to the Hospital Episode Statistics (HES) database, which contains in-hospital diagnosis and procedure data. US MarketScan includes individuals and their dependents covered by large US employer health insurance plans, and government and public organizations.

In each jurisdiction, the investigators will assemble a base cohort that includes all patients newly prescribed a DOAC for stroke prevention in AF. Study period will be from the date of the first DOAC approval for stroke prevention in AF at each site to the date of latest data availability at each site. All patients newly dispensed a DOAC (i.e. with no prescription for any oral anticoagulant in the prior year) with a diagnosis of AF within the 3 years prior to the date of the prescription will be eligible to be included into the study cohorts, given they present no exclusion criteria. The date of study cohort entry will be defined by the prescription (for CPRD) or dispensation (for all other sites) date of the newly prescribed DOAC. Patients will be censored at the earliest of death, end of healthcare coverage, or the end of the study period, whichever occurs first.

Exposure to a DOAC will be defined as a new prescription for a DOAC (apixaban, dabigatran, rivaroxaban) on the date of cohort entry. The investigators will use an analysis analogous to an intention-to-treat approach. The primary outcome will be defined as a hospitalization or emergency department visit for ischemic stroke or systemic embolization. The secondary outcomes will be: 1) major bleeding; 2) a composite of stroke (ischemic or hemorrhagic), systemic embolization, major bleeding or all-cause mortality; 3) myocardial infarction; 4) gastrointestinal bleeding; 5) intracranial bleeding; and 6) all-cause mortality.

The study cohort will be analyzed using a matched cohort design. In each participating site, three distinct study cohorts will be assembled, one for each of the following comparisons, nested in the same base cohort: 1) dabigatran vs. rivaroxaban, 2) dabigatran vs. apixaban, and 3) rivaroxaban vs. apixaban. DOAC users will be matched 1:1 to DOAC users on sex, age, cohort entry date, and propensity score (which will be constructed using a multivariable logistic regression model estimating the odds of being treated with DOACs, while adjusting for a number of pre-identified covariates to account for baseline differences at the time of cohort entry). Cox-proportional hazards regression models will be used to estimate adjusted hazards ratios (HRs) and corresponding 95% confidence intervals (CIs) for ischemic stroke or systemic embolization in the three cohorts. Meta-analyses of the site-specific results will be performed using random effects models. As secondary analyses, the composite outcome will be stratified by age (\<85 and ≥85) and sex. In addition, an as treated analysis using inverse probability of censoring weights (IPCW) will be performed to account for non-random censoring.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Ischemic Stroke Systemic Embolization Major Bleed Myocardial Infarction All-cause Mortality

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rivaroxaban vs dabigatran

Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with rivaroxaban or dabigatran at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.

Dabigatran (ATC B01AE07)

Intervention Type DRUG

Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.

Rivaroxaban (ATC B01AF01)

Intervention Type DRUG

Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.

Apixaban vs dabigatran

Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with apixaban or dabigatran at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.

Apixaban (ATC B01AF02)

Intervention Type DRUG

Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.

Dabigatran (ATC B01AE07)

Intervention Type DRUG

Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.

Apixaban vs rivaroxaban

Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with apixaban or rivaroxaban at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.

Apixaban (ATC B01AF02)

Intervention Type DRUG

Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.

Rivaroxaban (ATC B01AF01)

Intervention Type DRUG

Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Apixaban (ATC B01AF02)

Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.

Intervention Type DRUG

Dabigatran (ATC B01AE07)

Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.

Intervention Type DRUG

Rivaroxaban (ATC B01AF01)

Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Eliquis Pradaxa Xarelto

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a new prescription for an oral anticoagulant that had a diagnosis of atrial fibrillation or atrial flutter within the 3 years prior to the date of the prescription
* Patients aged 18 years or older (except Alberta, Nova Scotia, and Ontario, where patients will be aged at least 66 years or older)

Exclusion Criteria

* Patients with less than one year of data availability prior to cohort entry
* Patients with a diagnosis of valvular disease (including rheumatic heart disease) or prior cardiac valve surgery
* Patients with a diagnosis of venous thromboembolic disease in the year prior to cohort entry
* Patients who underwent hemodialysis in the 90 days prior to cohort entry
* Patients with a hip, femur, or knee surgery in the 30 days prior to cohort entry
* Patients with a diagnosis of antiphospholipid syndrome

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No